Corbus Pharmaceuticals Holdings Inc. (CRBP): Skating on Thin Ice? We Know the Answer – News Heater
Home  »  Business   »  Corbus Pharmaceuticals Holdings Inc. (CRBP): Skati...

Corbus Pharmaceuticals Holdings Inc. (CRBP): Skating on Thin Ice? We Know the Answer

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) went down by -11.36% from its latest closing price compared to the recent 1-year high of $2.29. The company’s stock price has collected -33.35% of loss in the last five trading sessions.

Is It Worth Investing in Corbus Pharmaceuticals Holdings Inc. (NASDAQ :CRBP) Right Now?

Plus, the 36-month beta value for CRBP is at 2.02. Opinions of the stock are interesting as 1 analysts out of 2 who provided ratings for Corbus Pharmaceuticals Holdings Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


The average price from analysts is $3.00, which is $1.77 above the current price. CRBP currently public float of 124.69M and currently shorts hold a 3.08% ratio of that float. Today, the average trading volume of CRBP was 984.88K shares.

CRBP’s Market Performance

CRBP stocks went down by -33.35% for the week, with a monthly drop of -48.50% and a quarterly performance of -48.82%, while its annual performance rate touched -84.89%. The volatility ratio for the week stands at 16.87% while the volatility levels for the past 30 days are set at 10.48% for Corbus Pharmaceuticals Holdings Inc.. The simple moving average for the period of the last 20 days is -37.23% for CRBP stocks with a simple moving average of -72.24% for the last 200 days.

Analysts’ Opinion of CRBP

Many brokerage firms have already submitted their reports for CRBP stocks, with ROTH Capital repeating the rating for CRBP by listing it as a “Neutral.” The predicted price for CRBP in the upcoming period, according to ROTH Capital is $3 based on the research report published on September 08th of the previous year 2020.

Jefferies gave a rating of “Hold” to CRBP, setting the target price at $2.50 in the report published on September 08th of the previous year.

CRBP Trading at -46.55% from the 50-Day Moving Average

After a stumble in the market that brought CRBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.83% of loss for the given period.

Volatility was left at 10.48%, however, over the last 30 days, the volatility rate increased by 16.87%, as shares sank -47.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.19% lower at present.

During the last 5 trading sessions, CRBP fell by -33.35%, which changed the moving average for the period of 200-days by -85.81% in comparison to the 20-day moving average, which settled at $0.3250. In addition, Corbus Pharmaceuticals Holdings Inc. saw -65.89% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CRBP starting from Moran Sean F., who purchase 15,000 shares at the price of $0.37 back on Mar 10. After this action, Moran Sean F. now owns 167,272 shares of Corbus Pharmaceuticals Holdings Inc., valued at $5,550 using the latest closing price.

Millian Craig Stuart, the Chief Operating Officer of Corbus Pharmaceuticals Holdings Inc., purchase 10,000 shares at $0.37 during a trade that took place back on Mar 10, which means that Millian Craig Stuart is holding 22,000 shares at $3,700 based on the most recent closing price.

Stock Fundamentals for CRBP

Current profitability levels for the company are sitting at:

  • -6350.09 for the present operating margin
  • -85.92 for the gross margin

The net margin for Corbus Pharmaceuticals Holdings Inc. stands at -5176.38. Equity return is now at value -57.90, with -37.40 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 5.89.

Leave a Comment

Your email address will not be published.




Download Free eBook For


100% free. stop anytime no spam